Tioga's lead product is
asimadoline, a proprietary,
peripherally restricted small molecule kappa opioid agonist,
originally discovered by
Merck KGaA of Darmstadt, Germany.
Asimadoline is currently in Phase 3 clinical development for the
treatment of irritable bowel syndrome (IBS)
...more
IBS is a common condition that is found in high prevalence throughout the world. Affected patients
experience recurrent episodes of abdominal pain or discomfort associated with a change in bowel pattern
...more